Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy

Ashish K Jha; Sneha Mithun; Nilendu C Purandare; Sneha A Shah; Archi Agrawal; Suyash S Kulkarni; Nitin Shetty; Venkatesh Rangarajan

doi:10.1097/MNM.0000000000000544

Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy

Ashish K Jha, Sneha Mithun, Nilendu C Purandare, Sneha A Shah, Archi Agrawal, Suyash S Kulkarni, Nitin Shetty, Venkatesh Rangarajan^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

PURPOSE: Transarterial radioembolization is used to treat primary and secondary liver malignancies. Two commercially available drugs are utilized for the purpose. The aim of our study is to compare the radiation dose delivered to the tumor by these drugs.

MATERIALS AND METHODS: This study included 86 patients (M : F - 7.6 : 1, median age=50.5 years), 46 patients were treated by Y-TheraSphere and 42 patients were treated by Y-SIRSphere. Activity administered in Y-TheraSphere and Y-SIRSphere was calculated using a modified partition model and a modified body surface area model, respectively. The radiation dose delivered by two drugs was calculated and compared in our study.

RESULT: Activity administered in Y-TheraSphere was significantly higher than that of Y-SIRSphere. Hence, the radiation dose delivered to the tumor by Y-SIRSphere was significantly lower (58.4%) than that of Y-TheraSphere (P=0.000).

CONCLUSION: As the radiation dose delivered by Y-SIRSphere was lower than Y-TheraSphere, we believe that the formula for Y-SIRSphere activity calculation needs to be modified so that the optimal dose can be delivered to the tumor.

Original language	English
Pages (from-to)	917-23
Number of pages	7
Journal	Nuclear Medicine Communications
Volume	37
Issue number	9
DOIs	https://doi.org/10.1097/MNM.0000000000000544
Publication status	Published - Sept 2016
Externally published	Yes

Keywords

Body Surface Area
Embolization, Therapeutic/methods
Female
Hepatic Artery
Humans
Liver Neoplasms/blood supply
Male
Microspheres
Middle Aged
Models, Biological
Radiotherapy Dosage
Yttrium Radioisotopes/administration & dosage

Access to Document

10.1097/MNM.0000000000000544

Cite this

Jha, A. K., Mithun, S., Purandare, N. C., Shah, S. A., Agrawal, A., Kulkarni, S. S., Shetty, N., & Rangarajan, V. (2016). Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy. Nuclear Medicine Communications, 37(9), 917-23. https://doi.org/10.1097/MNM.0000000000000544

@article{55a73fa331074458bae5b1fe560cd632,

title = "Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy",

abstract = "PURPOSE: Transarterial radioembolization is used to treat primary and secondary liver malignancies. Two commercially available drugs are utilized for the purpose. The aim of our study is to compare the radiation dose delivered to the tumor by these drugs.MATERIALS AND METHODS: This study included 86 patients (M : F - 7.6 : 1, median age=50.5 years), 46 patients were treated by Y-TheraSphere and 42 patients were treated by Y-SIRSphere. Activity administered in Y-TheraSphere and Y-SIRSphere was calculated using a modified partition model and a modified body surface area model, respectively. The radiation dose delivered by two drugs was calculated and compared in our study.RESULT: Activity administered in Y-TheraSphere was significantly higher than that of Y-SIRSphere. Hence, the radiation dose delivered to the tumor by Y-SIRSphere was significantly lower (58.4%) than that of Y-TheraSphere (P=0.000).CONCLUSION: As the radiation dose delivered by Y-SIRSphere was lower than Y-TheraSphere, we believe that the formula for Y-SIRSphere activity calculation needs to be modified so that the optimal dose can be delivered to the tumor.",

keywords = "Body Surface Area, Embolization, Therapeutic/methods, Female, Hepatic Artery, Humans, Liver Neoplasms/blood supply, Male, Microspheres, Middle Aged, Models, Biological, Radiotherapy Dosage, Yttrium Radioisotopes/administration & dosage",

author = "Jha, {Ashish K} and Sneha Mithun and Purandare, {Nilendu C} and Shah, {Sneha A} and Archi Agrawal and Kulkarni, {Suyash S} and Nitin Shetty and Venkatesh Rangarajan",

year = "2016",

month = sep,

doi = "10.1097/MNM.0000000000000544",

language = "English",

volume = "37",

pages = "917--23",

journal = "Nuclear Medicine Communications",

issn = "0143-3636",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "9",

}

Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy. / Jha, Ashish K; Mithun, Sneha; Purandare, Nilendu C et al.
In: Nuclear Medicine Communications, Vol. 37, No. 9, 09.2016, p. 917-23.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Impact of the activity calculation method used in transarterial radioembolization

T2 - a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy

AU - Jha, Ashish K

AU - Mithun, Sneha

AU - Purandare, Nilendu C

AU - Shah, Sneha A

AU - Agrawal, Archi

AU - Kulkarni, Suyash S

AU - Shetty, Nitin

AU - Rangarajan, Venkatesh

PY - 2016/9

Y1 - 2016/9

N2 - PURPOSE: Transarterial radioembolization is used to treat primary and secondary liver malignancies. Two commercially available drugs are utilized for the purpose. The aim of our study is to compare the radiation dose delivered to the tumor by these drugs.MATERIALS AND METHODS: This study included 86 patients (M : F - 7.6 : 1, median age=50.5 years), 46 patients were treated by Y-TheraSphere and 42 patients were treated by Y-SIRSphere. Activity administered in Y-TheraSphere and Y-SIRSphere was calculated using a modified partition model and a modified body surface area model, respectively. The radiation dose delivered by two drugs was calculated and compared in our study.RESULT: Activity administered in Y-TheraSphere was significantly higher than that of Y-SIRSphere. Hence, the radiation dose delivered to the tumor by Y-SIRSphere was significantly lower (58.4%) than that of Y-TheraSphere (P=0.000).CONCLUSION: As the radiation dose delivered by Y-SIRSphere was lower than Y-TheraSphere, we believe that the formula for Y-SIRSphere activity calculation needs to be modified so that the optimal dose can be delivered to the tumor.

AB - PURPOSE: Transarterial radioembolization is used to treat primary and secondary liver malignancies. Two commercially available drugs are utilized for the purpose. The aim of our study is to compare the radiation dose delivered to the tumor by these drugs.MATERIALS AND METHODS: This study included 86 patients (M : F - 7.6 : 1, median age=50.5 years), 46 patients were treated by Y-TheraSphere and 42 patients were treated by Y-SIRSphere. Activity administered in Y-TheraSphere and Y-SIRSphere was calculated using a modified partition model and a modified body surface area model, respectively. The radiation dose delivered by two drugs was calculated and compared in our study.RESULT: Activity administered in Y-TheraSphere was significantly higher than that of Y-SIRSphere. Hence, the radiation dose delivered to the tumor by Y-SIRSphere was significantly lower (58.4%) than that of Y-TheraSphere (P=0.000).CONCLUSION: As the radiation dose delivered by Y-SIRSphere was lower than Y-TheraSphere, we believe that the formula for Y-SIRSphere activity calculation needs to be modified so that the optimal dose can be delivered to the tumor.

KW - Body Surface Area

KW - Embolization, Therapeutic/methods

KW - Female

KW - Hepatic Artery

KW - Humans

KW - Liver Neoplasms/blood supply

KW - Male

KW - Microspheres

KW - Middle Aged

KW - Models, Biological

KW - Radiotherapy Dosage

KW - Yttrium Radioisotopes/administration & dosage

U2 - 10.1097/MNM.0000000000000544

DO - 10.1097/MNM.0000000000000544

M3 - Article

C2 - 27182686

SN - 0143-3636

VL - 37

SP - 917

EP - 923

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

IS - 9

ER -

Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this